Comparing the current results to its competitors, Neogenomics Inc reported Revenue increase in the 1 quarter 2026 by 11.13 % year on year. The revenue growth was below Neogenomics Inc 's competitors' average revenue growth of 11.22 %, achieved in the same quarter.
Neogenomics Inc 's Comment on Competition and Industry Peers
NeoGenomics operates in a competitive environment that includes national medical testing laboratories, hospital laboratories, and in-house physician laboratories across the United States. Some competitors possess greater financial resources and production capabilities, which may allow them to develop and market more effective service offerings. Technological advancements by competitors could also impact the relevance of NeoGenomics' services. In the pharmaceutical development sector, NeoGenomics competes with various Contract Research Organizations (CROs) and central reference laboratories, many of which are larger and provide a wider range of healthcare services. NeoGenomics focuses on oncology by offering a broad portfolio of tests with rapid turnaround times, proprietary tests, and enhanced post-test consultation services.
Overall company revenue, increased less, than total company revenues, at 11.13 % and lost market share, to approximately 2.29 %. << More on NEO Market Share.
*Market share is calculated based on total revenue.
September 10, 2025
On September 10, 2025, Pomerantz LLP announced an investigation into potential claims on behalf of investors in NeoGenomics, Inc. (NASDAQ: NEO), a leading cancer diagnostic and genomic testing company. The firm is examining various aspects that may have impacted the company s performance and, consequently, the interests of its investors. Interested parties are encouraged to reach out to Danielle Peyton at newaction@pomlaw.com(mailto:newaction@pomlaw.com) or by calling 646-581-9980, ext. 7980.This announcement comes during a time when NeoGenomics has reported a year-on-year revenue increase of 10.19% for the second quarter of 2025. However, while this growth is a positive indicator, it falls short of the aver...
Quest Diagnostics Inc operates as a leading provider of clinical laboratory and diagnostic information services, catering to patients, healthcare professionals, hospitals, and pharmaceutical companies. The company generates revenue through a comprehensive suite of diagnostic testing services, encompassing routine lab tests, advanced molecular diagnostics, and a variety of specialized tests tailored to support clinical decision-making and patient care.
Labcorp Holdings Inc operates as a major healthcare diagnostics company, providing clinical laboratory tests and services to healthcare providers, pharmaceutical companies, and government agencies. Their business model emphasizes delivering accurate and timely test results to aid in patient diagnosis, treatment, and monitoring.
Myriad Genetics Inc's business model revolves around providing molecular diagnostic testing services and developing innovative precision medicine solutions that help identify and personalize treatment options for patients across various medical specialties.
Natera Inc operates as a genetic testing company that provides non-invasive screening and diagnostic tests for reproductive health, oncology, and organ transplantation. The company's business model is built around offering cost-effective and accurate genetic testing solutions for both patients and healthcare providers. Natera primarily generates revenue by selling its proprietary tests and associated analysis services to customers, including hospitals, laboratories, and physicians.
Interpace Biosciences Inc operates upon a business model that involves providing molecular diagnostic tests and services for improved patient management and outcomes.
Sources:
Neogenomics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Neogenomics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
